Clinical Trial Update: Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

View source ↗

Summary

This clinical trial update summarizes patient experiences with Kesimpta and the subcutaneous formulation of Ocrevus in multiple sclerosis. The study, sponsored …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)
• Ocrevus (ocrelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Status: COMPLETED